Evidence map›Paper›PMID 27312803›Full record

ArticleJournal of the American Heart Association2016

Systematic Evaluation of the Cellular Innate Immune Response During the Process of Human Atherosclerosis.

Rogier A van Dijk, Kevin Rijs, Anouk Wezel, Jaap F Hamming, Frank D Kolodgie, Renu Virmani, Alexander F Schaapherder, Jan H N Lindeman

Open access · goldAbstract read
In one paragraph

Article in Journal of the American Heart Association, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 1 pooled it
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.

  1. Extreme Diversity of the Human Vascular Mesenchymal Cell Landscape.Journal of the American Heart Association · 2020
    Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Type-I interferons in atherosclerosis.The Journal of experimental medicine · 2020
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Rogier A van DijkDepartment of Vascular Surgery, Leiden University Medical Center, Leiden, The Netherlands.
Kevin RijsDepartment of Vascular Surgery, Leiden University Medical Center, Leiden, The Netherlands.
Anouk WezelDepartment of Vascular Surgery, Leiden University Medical Center, Leiden, The Netherlands.
Jaap F HammingDepartment of Vascular Surgery, Leiden University Medical Center, Leiden, The Netherlands.
Frank D KolodgieCVPath Institute Inc., Gaithersburg, MD.
Renu VirmaniCVPath Institute Inc., Gaithersburg, MD.
Alexander F SchaapherderDepartment of Transplantation Surgery, Leiden University Medical Center, Leiden, The Netherlands.
Jan H N LindemanDepartment of Vascular Surgery, Leiden University Medical Center, Leiden, The Netherlands Department of Transplantation Surgery, Leiden University Medical Center, Leiden, The Netherlands lindeman@lumc.nl.
Leiden University Medical Center · NLCVPath Institute · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe concept of innate immunity is well recognized within the spectrum of atherosclerosis, which is primarily dictated by macrophages. Although current insights to this process are largely based on murine models, there are fundamental differences in the atherosclerotic microenvironment and associated inflammatory response relative to humans. In this light, we characterized the cellular aspects of innate immune response in normal, nonprogressive, and progressive human atherosclerotic plaques. METHODS AND

resultsA systematic analysis of innate immune response was performed on 110 well-characterized human perirenal aortic plaques with immunostaining for specific macrophage subtypes (M1 and M2 lineage) and their activation markers, neopterin and human leukocyte antigen-antigen D related (HLA-DR), together with dendritic cells (DCs), natural killer (NK) cells, mast cells, neutrophils, and eosinophils. Normal aortae were devoid of low-density lipoprotein, macrophages, DCs, NK cells, mast cells, eosinophils, and neutrophils. Early, atherosclerotic lesions exhibited heterogeneous populations of (CD68(+)) macrophages, whereby 25% were double positive "M1" (CD68(+)/ inducible nitric oxide synthase [iNOS](+)/CD163(-)), 13% "M2" double positive (CD68(+)/iNOS(-)/CD163(+)), and 17% triple positive for (M1) iNOS (M2)/CD163 and CD68, with the remaining (≈40%) only stained for CD68. Progressive fibroatheromatous lesions, including vulnerable plaques, showed increasing numbers of NK cells and fascin-positive cells mainly localized to the media and adventitia whereas the M1/M2 ratio and level of macrophage activation (HLA-DR and neopterin) remained unchanged. On the contrary, stabilized (fibrotic) plaques showed a marked reduction in macrophages and cell activation with a concomitant decrease in NK cells, DCs, and neutrophils.

conclusionsMacrophage "M1" and "M2" subsets, together with fascin-positive DCs, are strongly associated with progressive and vulnerable atherosclerotic disease of human aorta. The observations here support a more complex theory of macrophage heterogeneity than the existing paradigm predicated on murine data and further indicate the involvement of (poorly defined) macrophage subtypes or greater dynamic range of macrophage plasticity than previously considered.

Indexed as

AortaAtherosclerosisDendritic CellsFemaleHLA-DR AntigensHumansImmunity, InnateImmunohistochemistryKiller Cells, NaturalMacrophagesMaleMast CellsMiddle AgedNeutrophilsHLA-DR Antigensaortaatherosclerosisimmune systeminflammationmacrophage

Identifiers

PMID27312803
PMCPMC4937250
OpenAlexW2433167375

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.